1. Basic Information
Disease Protected Against
Rotavirus is the leading cause of severe acute gastroenteritis in infants and young children globally. Before vaccination, rotavirus caused ~2.7 million cases of gastroenteritis, ~400,000 physician visits, ~70,000 hospitalizations, and ~20–60 deaths annually in U.S. children <5. Globally, rotavirus caused ~215,000 deaths/year in children <5 (pre-vaccine), predominantly in low-income countries. Transmission is fecal-oral. Almost all children are infected by age 3–5, regardless of sanitation quality.
CDC Schedule (U.S., 2025)
| Dose | Recommended Age | Notes |
|---|---|---|
| Dose 1 | 2 months | Minimum age 6 weeks; maximum age for dose 1 = 14 weeks 6 days |
| Dose 2 | 4 months | Minimum interval 4 weeks |
| Dose 3 (RotaTeq only) | 6 months | RotaTeq (RV5) requires 3 doses; Rotarix (RV1) requires 2 doses. All doses must be completed by 8 months 0 days. |
Source: CDC ACIP, 2025 schedule. The strict age window (must start by 14w6d, must finish by 8m0d) is due to a small background risk of intussusception in older infants unrelated to vaccination.
2. Pre-Licensure Clinical Trial Data
Current rotavirus vaccines were developed with intussusception safety specifically in mind, following the RotaShield experience. Both RotaTeq and Rotarix conducted very large pivotal trials.
| Metric | RotaTeq (RV5, Merck) | Rotarix (RV1, GSK) |
|---|---|---|
| Pivotal trial size | ~70,000 infants (REST trial); ~35,000 received RotaTeq | ~63,000 infants; ~31,500 received Rotarix |
| Efficacy against severe rotavirus gastroenteritis | ~98% (U.S./Europe); lower in low-income settings (~50–65%) | ~85–96% (high-income); lower in low-income settings (~50–65%) |
| Efficacy against any rotavirus hospitalization | ~96% | ~85–96% |
| Intussusception (pre-licensure) | No signal observed vs. placebo within 42 days (6 cases vs. 5 cases in placebo) | No signal observed vs. placebo within 31 days |
The REST (RotaTeq) and Rotarix pivotal trials are the largest pre-licensure vaccine trials ever conducted, with ~130,000+ infants combined. Both were specifically powered to evaluate intussusception risk.
Most Common Adverse Reactions
| Reaction | RotaTeq / Rotarix (Approx.) |
|---|---|
| Diarrhea | ~10–20% (mild, self-limited) |
| Vomiting | ~8–15% |
| Irritability | ~15–25% |
| Fever | ~10–20% |
Adverse reactions are generally mild and self-limited (1–3 days). Rates are comparable to placebo in the large trials, reflecting the high background rate of these symptoms in infants.
Key Limitations
- Intussusception at very low rates: Even the very large pivotal trials (N=130,000+) were not adequately powered to detect intussusception at rates of ~1–5 per 100,000 doses. This risk was identified and quantified post-licensure.
- Lower efficacy in low-income countries: Rotavirus vaccine efficacy is substantially lower in low-income settings, a phenomenon also observed with oral polio vaccine but not fully understood. Possible contributing factors include maternal antibody interference, gut microbiome differences, and malnutrition.
- Contraindication in SCID: Infants with severe combined immunodeficiency (SCID) can develop severe, prolonged vaccine-strain rotavirus gastroenteritis. SCID is now screened at birth in the U.S., allowing identification before the 2-month vaccination visit.
3. Post-Licensure Safety Data
Intussusception — Confirmed Post-Licensure Signal
Post-licensure VSD and international studies identified a small but statistically significant increased risk of intussusception following rotavirus vaccination, primarily in the 3–7 day window after the first dose.
- RotaTeq (RV5): Estimated ~1–1.5 excess cases of intussusception per 100,000 first doses (VSD data). Attributable fraction small relative to background risk of intussusception (~35 per 100,000 infant-years).
- Rotarix (RV1): Estimated ~1–5 excess cases per 100,000 first doses (international studies; higher estimates from some datasets).
- Risk-benefit: Studies estimate that rotavirus vaccination prevents ~50,000–70,000 U.S. hospitalizations annually while causing ~40–120 excess intussusception cases. The benefit-risk ratio is estimated at approximately 500–1,000 hospitalizations prevented per excess intussusception case.
The intussusception risk is acknowledged by ACIP, CDC, and WHO, and is included in product labeling. IOM (2012) concluded evidence favors acceptance of a causal relationship for rotavirus vaccine and intussusception.
Other Post-Licensure Findings
- Horizontal transmission: Vaccine-strain rotavirus can be shed in stool and transmitted to unvaccinated contacts. This is generally considered a benefit (indirect protection) but can cause disease in severely immunocompromised contacts.
- Porcine circovirus (PCV) contamination: In 2010, both RotaTeq and Rotarix were found to contain DNA fragments of porcine circovirus (PCV-1 and PCV-2). FDA determined this did not pose a safety risk, and vaccination continued. PCV is not known to cause disease in humans.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (Rotavirus (RotaTeq + Rotarix combined)):
| Metric | Value |
|---|---|
| U.S. doses administered (2006–2022) | 150,866,652 |
| Total VAERS AE reports | 19,899 |
| AE reporting rate (per 100,000 doses) | 13.2 |
| Total death reports | 476 |
| Death reporting rate (per 100,000 doses) | 0.316 |
| AE-to-Death ratio | 42:1 |
Source: Halma MT, Varon J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4010005. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
- Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
- Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
- Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
- Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
- Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma MT, Varon J. DARE-SAFE: A data analysis and reporting engine for safety signal detection and pharmacovigilance. Pharmacoepidemiology. 2025;4(1):5. DOI: 10.3390/pharma4010005. CC BY 4.0.
4. Documented Adverse Events
▶ Strong Evidence of Causal Association
- Intussusception: ~1–5 excess cases per 100,000 first doses within 3–7 days post-dose 1. IOM (2012) favored acceptance of causal relationship. Background risk (~35 per 100,000 infant-years) is higher than vaccine-attributable risk. Strong
- Diarrhea / vomiting: Mild, self-limited (10–20%). Strong
- Irritability: 15–25%; self-limited. Strong
- Vaccine-strain gastroenteritis in SCID infants: Severe, prolonged diarrhea in immunocompromised infants. Strong
▶ No Causal Association
- Kawasaki disease: An initial VAERS signal was investigated in VSD and found not to be associated. No Association
5. Disease Prevention Benefits
| Metric | Pre-Vaccine Era | Post-Vaccine Era (U.S.) |
|---|---|---|
| Rotavirus hospitalizations (annual, children <5) | ~55,000–70,000 | >90% reduction; ~4,000–6,000 hospitalizations/year |
| Rotavirus ER visits (annual, <5) | ~200,000 | ~80–85% reduction |
| Rotavirus deaths (annual, U.S., <5) | ~20–60 | <5/year |
| Global rotavirus deaths (2000 vs. 2022) | ~528,000 (2000) | ~128,000 (2022) — ~76% reduction |
Source: CDC Pink Book; WHO. Substantial herd protection has been observed, with declines in rotavirus disease in unvaccinated older children and adults.
6. Evidence Summary
Rotavirus vaccines have been studied in the largest pre-licensure trials in vaccine history (N=130,000+ combined), specifically designed to evaluate intussusception risk. The post-licensure identification of a small intussusception risk (~1–5 per 100,000 first doses) is an example of the surveillance system functioning as designed—detecting a risk too small to be identified even in the very large pre-licensure trials. The benefit-risk ratio strongly favors vaccination. The primary evidence gap is the lower efficacy in low-income countries, an active area of research.
| Domain | Evidence Grade |
|---|---|
| Efficacy (severe rotavirus disease, high-income) | Strong |
| Intussusception risk | Strong |
| Efficacy (low-income settings) | Moderate |
7. Key References
- Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. (REST trial; N=68,038)
- Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. (Rotarix pivotal trial; N=63,225)
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
- Weintraub ES, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014;370(6):513–519.
- Yih WK, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503–512. (VSD study)
- CDC. Pink Book — Rotavirus chapter. cdc.gov/pinkbook
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov